Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
san francisco blog main
san francisco top stories
9
×
startups
9
×
biotech
boston blog main
raleigh-durham blog main
san diego blog main
san diego top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national top stories
new york blog main
new york top stories
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
cancer immunotherapy
abbvie
alzheimer's disease
eli lilly
fda
medicare
pfizer
biogen
clinical trials
investing
What
drug
9
×
roundup
bio
companies
acquisitions
alzheimer’s
annual
attention
biggest
biotech
ceo
disease
nash
news
patients
price
prices
therapy
today
week
ahead
albert
ambien
american
approval
approved
asco
assessed
attendees
biogen’s
biopharmaceutical
bourla
build
building
buy
camp’s
cancer
cash
chicago
city
Language
unknown
unset
Current search:
startups
×
drug
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Virtual Physical Therapy Firms Reflexion and MindMaze Probe Markets
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed